









Markets
/
Stocks
/
nasdaq-bblg
/

Bone Biologics Corp

BBLG

2.110USD

-0.030-1.40%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

592.65KMarket Cap

LossP/E TTM



Bone Biologics Corp

2.110

-0.030-1.40%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

274 / 506

Overall Ranking

457 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

22.500

Target Price

+951.40%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 393.39.

Fairly Valued

The company’s latest PE is -0.34, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 151.13K shares, increasing 43.23% quarter-over-quarter.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 7.04, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.04

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.43

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.34, which is -73.87% below the recent high of -0.09 and -10.03% above the recent low of -0.38.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 274/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03. The average price target for Bone Biologics Corp is 22.50, with a high of 22.50 and a low of 22.50.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 2.78, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 3.53 and the support level at 1.35, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.78

Change

-0.01

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.036

Neutral

RSI(14)

44.629

Neutral

STOCH(KDJ)(9,3,3)

36.103

Buy

ATR(14)

0.326

High Vlolatility

CCI(14)

-34.942

Neutral

Williams %R

92.664

Oversold

TRIX(12,20)

-0.586

Sell

StochRSI(14)

67.901

Sell

Moving Average

Sell(4)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MA5

2.112

Sell

MA10

2.110

Neutral

MA20

2.171

Sell

MA50

2.463

Sell

MA100

2.427

Sell

MA200

1.686

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Intracoastal Capital, L.L.C.

148.50K

Sabby Management, LLC

1.65K

Frelick (Jeffrey)

359.00

+0.84%

Walsh (Deina H)

313.00

Tower Research Capital LLC

304.00

-46.19%

BofA Global Research (US)

4.00

+33.33%

Meikle (Phillip Terry II)

2.00

Geode Capital Management, L.L.C.

4.03K

+57.64%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.10, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.80. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.